Xtant Medical Holdings, Inc.XTNTNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+34.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+34.3%/yr
Annual compound
Percentile
P93
Near historical high
vs 3Y Ago
2.4x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 78.52% |
| 2023 | 46.01% |
| 2022 | 5.17% |
| 2021 | 32.42% |
| 2020 | -29.51% |
| 2019 | -45.24% |
| 2018 | -30.28% |
| 2017 | -28.43% |
| 2016 | 33.94% |
| 2015 | 76.46% |